Skip to main content

Table 2 Frequency of HCV NS5A clinically relevant resistance-associated substitution (RAS) in mono-infected and HIV/HCV co-infected patients according to HCV subtype

From: Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil

  HCV 1a (n = 41) HIV/HCV 1a (n = 77) p-value# HCV 1b (n = 84) HIV/HCV 1b (n = 9) p-value# HCV 3a (n = 31) HIV/HCV 3a (n = 15) p-value#
RAS (+) (n, %) 6 (14.6%) 3 (3.9%) 0.063 5 (6.0%) 1 (11.1%) 0.467 7 (22.6%) 0 (0%) 0.078
RAS (−) (n, %) 35 (85.4%) 74 (96.1%)   79 (94.0%) 8 (88.9%)   24 (77.4%) 15 (100%)  
  1. HCV Hepatitis C virus and HIV Human immunodeficiency virus
  2. Clinically relevant resistance-associated substitution (RAS) interpreted according to cited references [5, 23, 27, 33, 39,40,41,42]
  3. #Fisher’s exact test